The global cervical cancer diagnostics market is projected to grow at a compound annual growth rate (CAGR) of about 5% from 2026 to 2034, expanding from $4.4 billion in 2025 to $7.1 billion by 2034. This growth is fueled by rising cervical cancer prevalence, increased awareness of early screening, and adoption of advanced diagnostic technologies like HPV testing, liquid-based cytology, and AI-powered tools. Government screening programs and improved healthcare infrastructure, especially in emerging economies, are enhancing access to diagnostics. North America currently leads the market, supported by established screening initiatives and reimbursement policies, while Asia-Pacific is emerging rapidly due to rising healthcare investments and screening efforts.
